Fluoxetine in acute treatment of children and adolescents with obsessive-compulsive disorder: a systematic review and meta-analysis.

Background: Obsessive-compulsive disorder (OCD) is a common psychiatric illness in children and adolescents. Previous evidence suggests that fluoxetine is effective in the treatment of OCD in children and adolescents. However, those studies had small sample sizes. As a result, a systematic review, which is a more powerful method to calculate the true effect size, can be applied to examine the efficacy, acceptability and tolerability of fluoxetine in the treatment of OCD in children and adolescents.Objectives: The aims of this study were to review the efficacy, acceptability and tolerability of fluoxetine in the treatment of OCD in children and adolescents.Study appraisal and synthesis methods: The titles and abstracts collected from electronic databases were evaluated. Then, the full-text versions of relevant studies were thoroughly assessed and extracted.Results: A total of 188 randomized patients in three RCTs of fluoxetine versus placebo and one RCT of fluoxetine versus citalopram were included in this review. Considering efficacious outcomes, the pooled mean change score of the CY-BOCS in the fluoxetine-treated group was significantly greater than that in the placebo-treated group. Additionally, the CGI-S in the fluoxetine-treated group and the pooled mean change score of the NIMH-OC were also significantly different from those in the placebo-treated group.Limitation: This review included studies with small sample sizes.Conclusions and implications of key findings: Fluoxetine is associated with a significantly greater reduction in OCD severity, as measured by the CY-BOCS, NIMH-OC and CGI-S, in children and adolescents. Additionally, it is well tolerated in children and adolescents. The acceptability is comparable to that of the placebo-treated group. Nonetheless, further large prospective trials should be conducted to confirm these outcomes.

Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis.

BACKGROUND: Recent randomized controlled trials indicated that aripiprazole was the effective treatment for children and adolescents with autism spectrum disorder (ASD). OBJECTIVE: This study systematically reviewed the efficacy, acceptability and tolerability of aripiprazole in treatment of ASD children and adolescents. DATA SOURCES: Electronic search of databases including, Scopus, PubMed, CINAHL and Cochrane Controlled Trials Register was performed in July 2017. METHODS: The full-text versions of included trials were meticulously evaluated and extracted. The main efficacious outcomes consisted of pooled mean change scores of the standardized rating scales for ASD and the pooled response rate. RESULTS: A total of 408 randomized patients from eligible trials were included for synthesizing in this meta-analysis. The pooled mean change scores in aripiprazole-treated group for the Aberrant Behavior Checklist (ABC)-Irritability, ABC-Hyperactivity/noncompliance, ABC-Inappropriate speech and ABC-Stereotypic behavior were significantly greater than those of the placebo-treated group. Unfortunately, the significant difference between two groups was not found for ABC-Lethargy/social withdrawal. The overall pooled response rate of the aripiprazole-treated group was significantly higher than that of the placebo-treated group. The pooled overall discontinuation rate in aripiprazole-treated group was significantly better than that of placebo-treated group. The pooled discontinuation rates due to adverse events in aripiprazole-treated group significantly differed from the placebo-treated group (RR [95% CI] of 1.43 [0.65, 3.18], I 2=0%). LIMITATION: A small number of studies were gathered in this review. CONCLUSION: Aripiprazole has efficacy in the treatment of behavioral disturbances, including irritability, hyperactivity/noncompliance, inappropriate speech and stereotypic behavior found in ASD children and adolescents; however, it could not improve the lethargy/social withdrawal in such patients. The present evidence also indicates that it is safe, acceptable and tolerable in such treatment. As a small sample size, further well-defined and large sample size studies should be conducted to warrant those findings.

Risperidone for children and adolescents with autism spectrum disorder: a systematic review.

BACKGROUND: Various clinical trials suggested that risperidone was beneficial in the treatment of autism spectrum disorder (ASD) in children and adolescents. OBJECTIVE: The aim of this systematic review was to determine the efficacy, acceptability and tolerability of risperidone in the treatment of children and adolescents with ASD. DATA SOURCES: The databases of Scopus, PubMed, CINAHL and Cochrane Controlled Trials Register were searched in February 2017. STUDY ELIGIBILITY CRITERIA PARTICIPANTS AND INTERVENTIONS: Eligible RCTs of risperidone in the treatment of child and adolescent patients with ASD. Languages were not restricted. STUDY APPRAISAL AND SYNTHESIS METHODS: The full-text versions of relevant studies were thoroughly assessed and extracted. The primary efficacy of outcome was the pooled response rate and the pooled mean changed scores of the standardized rating scales for ASD. RESULTS: A total of 372 randomized subjects from seven RCTs were included in this review. In acute treatment, the pooled mean change score of the Aberrant Behavior Checklist for irritability subscale (ABC-I) and response rate for the risperidone-treated group had a greater significance than that of the placebo-treated group. In the long-term treatment, the pooled mean change score of the CARS in the risperidone-treated group was significantly greater than that in the placebo-treated group. According to the discontinuation phase, the overall pooled relapse rate of the risperidone-treated group was significantly less than that of the placebo-treated group. The rates of pooled overall discontinuation and discontinuation due to adverse events rates were not different between the two groups in acute and long-term treatments. LIMITATIONS: A small study was included in the current review. CONCLUSION: In relation to the current systematic review, risperidone is efficacious in the treatment of symptoms in children and adolescents with ASD. Although its acceptability is comparable to placebo, treatment with risperidone is well tolerated in children and adolescents with ASD.

Validity and Reliability of Adult ADHD Self-Report Scale Thai Version (ASRS-V1.1 TH).

BACKGROUND: The adult ADHD Self-Report Scale Thai version (ASRS-V1.1) (18 items) is a questionnaire for screening adult ADHD. AIM: To test the validity and reliability of the 18-question ASRS-V1.1 Thai version (ASRS-V1.1 TH) as a screening tool for adult ADHD. METHODS: The original 18-question ASRS-V1.1 version was translated into Thai. The process was composed of forward-translation, synthesis of the translation, and back translation. Cross cultural adaptation, field testing, and final adjustment were completed consecutively. The 18-question ASRS-V1.1 TH were sent to 1,500 parents of kindergarten and elementary school students in Bangkok, Thailand. The diagnostic interview was randomly selected for 50 parents from the positive result group and 50 parents from the negative result group. The clinical interview for confirming diagnosis was run by 3 psychiatrists who were blinded to the results and used DSM-5 ADHD criteria for diagnosis. RESULTS: The 18-question ASRS-V1.1 TH had satisfactory internal consistency (Cronbach's alpha = 0.92: Cronbach's alpha = 0.87 for inattentive scale, Cronbach's alpha = 0.84 for hyperactive / impulsive scale). For testing the criteria validity, the questionnaire has an adequate. The AUC from the first 6 questions was 0.80 (95% CI: 0.68-0.92) while from the 18 questions was 0.71(95% CI: 0.55-0.86). CONCLUSIONS: The 18-question ASRS-V1.1TH is a psychometrically reliable and valid measure for screening adult ADHD in Thai clinical samples, especially the first 6 questions of the questionnaire.

Quetiapine monotherapy versus placebo in the treatment of children and adolescents with bipolar depression: a systematic review and meta-analysis.

BACKGROUND: Some studies have indicated the efficacy of quetiapine in the treatment of bipolar depression in adult patients. However, its efficacy has been not shown in child and adolescent patients. OBJECTIVE: This systematic review purposefully determined the efficacy and acceptability of quetiapine in the treatment of children and adolescents with bipolar depression. DATA SOURCES: A database search of EMBASE, PubMed, CINAHL, and Cochrane Controlled Trials Register was carried out in March 2016. All randomized controlled trials (RCTs) of bipolar depression in children and adolescents were considered for inclusion in this review. STUDY ELIGIBILITY CRITERIA PARTICIPANTS AND INTERVENTIONS: RCTs of quetiapine in the treatment of child and adolescent patients with bipolar depression with end point outcomes were included in this study. Languages were not limited. STUDY APPRAISAL AND SYNTHESIS METHODS: The full-text versions of relevant clinical studies were thoroughly examined and extracted. The primary efficacy of outcome was measured by using the pooled mean-changed scores of the rating scales for bipolar depression. However, the response and remission rates were also measured. RESULTS: A total of 251 randomized patients in the three RCTs of quetiapine versus placebo in the treatment of bipolar depression for children and adolescents were eligible in this review. The pooled mean-changed score of the quetiapine-treated group was not greater than that of the placebo-treated group. Similarly, the pooled response and remission rates were not different between the two groups. The pooled overall discontinuation rate and the discontinuation rate due to adverse events were not different between the two groups. LIMITATIONS: Limited studies were eligible in this review. CONCLUSION: According to the findings in this review, quetiapine may not be efficacious in the treatment of bipolar depression in children and adolescents. Its acceptability, however, was comparable to a placebo. Therefore, the use of quetiapine in children and adolescents with bipolar depression is not recommended. Further well-defined clinical studies should be performed to confirm these outcomes.